December 5, 2017 / 6:43 AM / 11 days ago

BRIEF-Gensight Biologics Reports Positive Results From Phase I/Ii Study Of Gs010

Dec 5 (Reuters) - GENSIGHT BIOLOGICS SA:

* GENSIGHT BIOLOGICS REPORTS POSITIVE LONG-TERM VISUAL ACUITY GAINS AND SAFETY RESULTS FROM PHASE I/II STUDY OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON)

* CONFIRMATION OF THE FAVORABLE LONG-TERM SAFETY PROFILE OF GS010‍​

* SIGNIFICANT IMPROVEMENT OF VISUAL ACUITY AT 2.5 YEARS OF FOLLOW-UP IN CERTAIN LHON PATIENTS

* LHON PATIENTS WITH LESS THAN 2 YEARS OF ONSET OF VISUAL LOSS PRIOR TO TREATMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below